Felbamate: Clinical and molecular aspects of a unique antiepileptic drug

被引:16
作者
Brown, WM
Aiken, SP
机构
[1] Univ Tasmania, Dept Anat & Physiol, Hobart, Tas 7001, Australia
[2] Univ St Andrews, Sch Biol & Med Sci, St Andrews KY16 9TS, Fife, Scotland
来源
CRITICAL REVIEWS IN NEUROBIOLOGY | 1998年 / 12卷 / 03期
关键词
felbamate; epilepsy; pharmacotherapy; antiepileptic drug (AED); aplastic anemia; gamma-aminobutyric acid (GABA); N-methyl-D-aspartate (NMDA); liver failure; toxicity;
D O I
10.1615/CritRevNeurobiol.v12.i3.30
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Felbamate was launched in 1993 in the U.S. as a "new generation" antiepileptic drug (AED) with a unique mechanism of action. It proved efficacious in patients refractory to other AEDs and was particularly beneficial in children suffering from Lennox-Gastaut syndrome, being the first drug shown to be effective at treating this condition in controlled trials. Following the occurrence of rare cases of aplastic anemia and of hepatic failure associated with the use of felbamate during early 1994, a "black-box" warning was added to the drug's package insert. Despite this, felbamate continues to be used in many patients, although not as a first-line treatment. Felbamate's dual mechanism of action-enhancing the GABA system while inhibiting excitatory amino acid responses-may explain its efficacy in a broad range of epileptic patients. A better understanding of this mechanism may lead to the development of felbamate-like drugs with a better side effect profile.
引用
收藏
页码:205 / 222
页数:18
相关论文
共 191 条
[1]   Tiagabine - A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy [J].
Adkins, JC ;
Noble, S .
DRUGS, 1998, 55 (03) :437-460
[2]  
ADUSUMALLI VE, 1993, DRUG METAB DISPOS, V21, P1079
[3]   EFFECT OF FELBAMATE ON PLASMA-LEVELS OF CARBAMAZEPINE AND ITS METABOLITES [J].
ALBANI, F ;
THEODORE, WH ;
WASHINGTON, P ;
DEVINSKY, O ;
BROMFIELD, E ;
PORTER, RJ ;
NICE, FJ .
EPILEPSIA, 1991, 32 (01) :130-132
[4]   PROPOSAL FOR REVISED CLASSIFICATION OF EPILEPSIES AND EPILEPTIC SYNDROMES [J].
不详 .
EPILEPSIA, 1989, 30 (04) :389-399
[5]   Felbamate in therapy-resistant epilepsy: An Italian experience [J].
Avanzini, G ;
Canger, R ;
DallaBernardina, B ;
Vigevano, F ;
Aguglia, U ;
Albano, C ;
Antonini, L ;
Battaglia, S ;
Battino, D ;
Benna, P ;
Besana, D ;
Antonelli, C ;
Binelli, S ;
Biondi, R ;
Boniver, C ;
Buti, D ;
Canziani, F ;
Capovilla, G ;
Casara, G ;
Casazza, M ;
Cernibori, A ;
Chindemi, A ;
Cianchetti, C ;
Cilio, MR ;
Coppola, G ;
Cremonte, M ;
DAgostino, V ;
Daniele, O ;
DeMarco, P ;
DeMaria, G ;
DiCosmo, F ;
DiPerri, R ;
Durisotti, C ;
Elia, M ;
Fois, A ;
Fontana, E ;
Franceschetti, S ;
Gaggero, R ;
Galeone, D ;
Gallitto, G ;
Gianelli, L ;
Rossi, PG ;
Giubergia, S ;
Gobbi, G ;
Guarneri, B ;
LaSelva, L ;
Lanzi, G ;
Laurienzo, P ;
Lenti, C ;
Lunardi, G .
EPILEPSY RESEARCH, 1996, 25 (03) :249-255
[6]   The effect of age on the apparent clearance of felbamate: A retrospective analysis using nonlinear mixed-effects modeling [J].
Banfield, CR ;
Zhu, GRR ;
Jen, JF ;
Jensen, PK ;
Schumaker, RC ;
Perhach, JL ;
Affrime, MB ;
Glue, P .
THERAPEUTIC DRUG MONITORING, 1996, 18 (01) :19-29
[7]   Recent advances in the pharmacotherapy of epilepsy [J].
Bazil, MK ;
Bazil, CW .
CLINICAL THERAPEUTICS, 1997, 19 (03) :369-382
[8]   Determination of felbamate concentration in pediatric samples by high-performance liquid chromatography [J].
Behnke, CE ;
Reddy, MN .
THERAPEUTIC DRUG MONITORING, 1997, 19 (03) :301-306
[9]  
BENMENACHEM E, 1995, EPILEPSY RES, V21, P231
[10]  
Bennett GD, 1996, J PHARMACOL EXP THER, V279, P1237